Transcatheter aortic valve replacement (TAVR) was first approved in 2011 for use in patients with severe aortic stenosis who are ineligible for surgery. In 2019, TAVR received approval for use in patients with severe aortic stenosis who are at low risk for death or complications due to open-heart surgery. Sammy Elmariah, MD, MPH, associate professor of medicine and chief of Interventional Cardiology at the University of California San Francisco, discusses the state of progress and ongoing developments in TAVR.
Special Collections
Clinician POV
Cardiologist Marat Fudim, MD, MHS, discusses the importance of myocardial contractility in the treatment of heart failure with reduced ejection fraction and the need to embrace novel heart failure treatment options.
This Q&A was edited for clarity and length. Reviewed July 2022
